Smoke Inhalation Patients
Conditions
Keywords
Smoke inhalation injury, Acute kidney injury, Intensive care unit, Burns, Prognosis, Hydroxocobalamin
Brief summary
In Europe, hydroxocobalamin (cyanokit) has been used for suspicion of cyanide intoxication associated with the inhalation of fire smoke (1). However, the impact of hydroxocobalamin on outcome has never been thoroughly evaluated. While hydroxocobalamin has long been presented as being side-effect free, recent data suggest that in patients with severe burns, its use was associated with the occurrence of acute renal failure by intra tubular precipitation of oxalate crystals (2, 3). The purpose of this observational study is to investigate the association between use of hydroxocobalamin and outcome after smoke inhalation.
Detailed description
In Europe, hydroxocobalamin (cyanokit) is the antidote recommended by expert consensus in cases of suspicion of cyanide intoxication associated with the inhalation of fire smoke (1). However, cyanokit has never been evaluated in this indication. Clinical data suggest that in patients with severe burns, its use is associated with the occurrence of acute kidney injury by intra tubular precipitation of oxalate crystals (2, 3). The purpose of this observational study is to investigate the association between use of hydroxocobalamin and outcome after smoke inhalation. The results of this study should guide future research and advice on the benefit-risk ratio of hydroxocobalamin.
Interventions
There is no intervention planned (observational)
Sponsors
Saint-Louis Hospital, Paris, France
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Admission in ICU with smoke inhalation diagnosed
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| in ICU mortality | through study completion, an average of 1 year | mortality in ICU or at day 90 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| in ICU acute kidney injury (based on the KDIGO definition) | through study completion, an average of 1 year | AKI in ICU or at day 90 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Major Adverse Kidney Events | through study completion, an average of 1 year | MAKE in ICU or at day 90 |
| in ICU length of stay alive | through study completion, an average of 1 year | through study completion, an average of 1 year |
Countries
France
Outcome results
None listed